ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

February 22, 2022

Study Completion Date

April 14, 2022

Conditions
Age-related Macular Degeneration
Interventions
COMBINATION_PRODUCT

Subcutaneous elamipretide through the elamipretide delivery system

Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.

COMBINATION_PRODUCT

Subcutaneos placebo through the elamipretide delivery system

Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.

Trial Locations (37)

14620

Retina Associates of Western New York, Rochester

21209

The Retina Care Center, Baltimore

21740

Cumberland valley retina consultants, Hagerstown

22903

University of Virginia, Department of Ophthalmology, Charlottesville

27705

Duke Eye center, Durham

30909

Southeast Retina Center, PC, Augusta

33136

Bascom Palmer Eye Institute, Miami

33143

MedEye Associates, Miami

33418

Bascom Palmer Eye Institute, Palm Beach Gardens

33880

Center for Retina and Macular Disease, Winter Haven

37203

Tennessee Retina, Nashville

45202

Sterling Research Group, Cincinnati

49202

Specialty Eye Institute, Jackson

57701

Black Hills Regional Eye Institute, Rapid City

73104

Oklahoma University Health Sciences Center, Oklahoma City

76102

Ophthalmology Associates, Fort Worth

76104

Texas Retina Associates, Fort Worth

77030

Retina Consultants of Houston, PA, Houston

77494

Retina Consultants of Houston, Katy

78503

Valley Retina Institute, PA, McAllen

78705

Retina Research Center, PLLC, Austin

79606

Retina Research Institute of Texas, Abilene

85014

Retinal Research Institute, LLC, Phoenix

85021

Arizona Retina & Vitreous Consultants, Phoenix

85053

Retinal Research Institute, LLC, Phoenix

85254

Global Retina Institute, Scottsdale

85381

Associated Retina Consultants, Ltd., Peoria

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

92260

Retina Institute of California Medical Group, Palm Desert

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

97221

Retina Northwest, P.C, Portland

02114

Ophthalmic Consultants of Boston, Boston

01107

New England Retina Consultants, Springfield

07003

Retina Center of New Jersey LLC, Bloomfield

07666

New Jersey Retina, Teaneck

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT03891875 - ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA | Biotech Hunter | Biotech Hunter